Lumature Wealth Partners’s Heron Therapeutics HRTX Stock Holding History

Lumature Wealth Partners’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$969	Hold	835	–	–	﹤0.01%	366
2023 Q1	$1.26K	Hold	835	–	–	﹤0.01%	366
2022 Q4	$2.09K	Hold	835	–	–	﹤0.01%	362
2022 Q3	$4K	Hold	835	–	–	﹤0.01%	355
2022 Q2	$2K	Hold	835	–	–	﹤0.01%	377
2022 Q1	$5K	Hold	835	–	–	﹤0.01%	375
2021 Q4	$8K	Hold	835	–	–	﹤0.01%	348
2021 Q3	$9K	Hold	835	–	–	﹤0.01%	335
2021 Q2	$13K	Hold	835	–	–	0.01%	281
2021 Q1	$14K	Buy	+835	New	+$14.9K	0.01%	275

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Lumature Wealth Partners's HRTX Position: Q2 2023 in Review

Lumature Wealth Partners held its Heron Therapeutics (HRTX) position steady in Q2 2023 at 835 shares worth $969. The position accounts for ﹤0.01% of the portfolio, ranked #366.

Lumature Wealth Partners first reported a position in HRTX in Q1 2021 and has held it in 10 quarters since. The position peaked at $14K in Q1 2021. 149 funds tracked by Wall St. Rank hold HRTX as of Q2 2023.

Lumature Wealth Partners held 835 shares of Heron Therapeutics worth $969 as of Q2 2023.
Lumature Wealth Partners left its Heron Therapeutics share count unchanged in Q2 2023.
Heron Therapeutics made up ﹤0.01% of Lumature Wealth Partners's portfolio in Q2 2023, its #366 holding.
Lumature Wealth Partners first reported a position in Heron Therapeutics in Q1 2021 and has held it in 10 quarters since.
Lumature Wealth Partners's Heron Therapeutics position peaked at $14K in Q1 2021.
149 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2023.

Based on Lumature Wealth Partners's 13F filing for Q2 2023, filed 14 Aug 2023.